CAS NO: | 273404-37-8 |
规格: | ≥98% |
包装 | 价格(元) |
2mg | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
250mg | 电议 |
Molecular Weight (MW) | 508.99 |
---|---|
Formula | C24H33ClN4O6 |
CAS No. | 273404-37-8 |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Solubility (In vitro) | DMSO: 100 mg/mL warming (196.46 mM) |
Water:<1 mg/mL (slightly soluble or insoluble) | |
Ethanol: 100 mg/mL warming (196.46 mM) | |
Other info | Solubility (In vivo): 2% DMSO+30% PEG 300+ddH2O: 5 mg/mL Synonym: VX 765, VX765, VX-765, Belnacasan Chemical Name: (S)-1-((S)-2-(4-amino-3-chlorobenzamido)-3,3-dimethylbutanoyl)-N-((2R,3S)-2-ethoxy-5-oxotetrahydrofuran-3-yl)pyrrolidine-2-carboxamide SMILES Code: O=C([C@H]1N(C([C@@H](NC(C2=CC=C(N)C(Cl)=C2)=O)C(C)(C)C)=O)CCC1)N[C@@H](C3)[C@H](OCC)OC3=O |
General | In a CIA mouse model, VX-765 significantly reduced the inflammation scores in a dose-dependent manner. In addition, 100 mg/kg VX-765 was as efficacious as 5 mg/kg Prednisolone. |
---|---|
Animal model | Collagen-induced arthritis (CIA) mouse model |
Formulation | VX-765 is dissolved in 25% Cremophor EL |
Dosages | 10, 25, 50 or 100 mg/kg |
Administration | p.o.; b.i.d.; for 24 days. |
References | [1] Wannamaker W, et al. J Pharmacol Exp Ther. 2007, 321(2), 509-516. |
Dose response of VX-765 in LPS-induced IL-1β production in vivo. Wannamaker W, et al. J Pharmacol Exp Ther. 2007 May;321(2):509-16. | Effects of VX-765 on ear swelling induced by oxazolone.J Pharmacol Exp Ther. 2007 May;321(2):509-16. | |